ArticleAntimicrobial agents and chemotherapy2021
Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.Infection · 2022Pooled it
- BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole.The Journal of antimicrobial chemotherapy · 2026Article
- Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii.PloS one · 2026Article
- Culture media affects accuracy of prediction of metallo-β-lactamases mediated resistance to imipenem.PloS one · 2026Article
- Ceftazidime retainsmSphere · 2025Article
- Bicarbonate Within: A Hidden Modulator of Antibiotic Susceptibility.Antibiotics (Basel, Switzerland) · 2025Review
- Cefiderocol in Combating Carbapenem-ResistantBiomedicines · 2024Review
- Polymyxins retainAntimicrobial agents and chemotherapy · 2024Article
- Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024Review
- What's the Matter with MICs: Bacterial Nutrition, Limiting Resources, and Antibiotic Pharmacodynamics.Microbiology spectrum · 2023Article
- Antimicrobial Susceptibility Testing Performed in RPMI 1640 Reveals Azithromycin Efficacy against Carbapenem-Resistant Acinetobacter baumannii and PredictsAntimicrobial agents and chemotherapy · 2023Article
- Article
- Immunological Evaluation of Individuals Infected withArchives of Razi Institute · 2022Article
- Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options.Infectious diseases and therapy · 2022Review
- Systematic Review of Antimicrobial Combination Options for Pandrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- New Perspectives on Antimicrobial Agents: Cefiderocol.Antimicrobial agents and chemotherapy · 2021Review
- Carbapenem-resistantJournal of research in pharmacy practiceReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Recently, we reported rifabutin hyperactivity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.